
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker

Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 13, 2026
BlackRock reports Protalix holding at September 30
NYSE American: $PLXEnzyme therapy salesPRX-115 trialOrder timing and equity issuance
PLX Stock Hub: Protalix BioTherapeutics News, Elfabrio and PRX-115
Protalix earned $3.961 million in the September quarter, with higher product deliveries to its Fabry disease partner Chiesi. The $25 million milestone received in March increased nine-month results and was specific to that European approval. The cash question is whether recurring partner orders can fund manufacturing and development without further equity issuance. Cash and short-term bank deposits were $48.538 million at September 30, while Protalix sold shares during and after the quarter. September Form 10-Q · November 10 financial update.
Full research report · PDF
Protalix BioTherapeutics ($PLX), research updated November 18, 2026
16 pages on Elfabrio, Elelyso, PRX-115, working capital, cash conversion and dilution. For personal use only: redistribution prohibited.
Next fixed financial checkpoint
December 31, 2026 · Fiscal year-end
December 31 closes the period covered by the $78 million to $83 million revenue outlook. Protalix said November 10 that it expects to meet or exceed the range. It had not announced a date for reporting annual results as of November 17. November outlook · Investor calendar.
For clinical development, Protalix targets the second half of 2027 for results from the Phase 2 RELEASE gout study. Study and timing.
PLX stock at a glance
Chart analysis · JC
Technical chart analysis of $PLX with bull and bear scenarios on JC Just Charts.
Cash and short-term deposits · September 30
$48.538M
Cash of $22.035M and deposits of $26.503M. Balance sheet.
Operating cash provided · Nine months
$15.529M
Period includes the March milestone. Cash flow statement.
2026 revenue outlook · November 10
$78–83M
Company expects to meet or exceed the range. Annual outlook.
Where Protalix stands now
The business has two commercial enzyme therapies and a pipeline drawing on their funding. Chiesi orders Elfabrio for Fabry disease. Pfizer buys the drug substance used to make Elelyso. Fiocruz buys the Gaucher therapy for Brazil. Protalix recognizes sales on delivery. Orders into a partner’s inventory can move faster or slower than demand from patients. Elfabrio economics · Elelyso and Brazil.
Cash test: Protalix collected about $9.3 million from Chiesi and $3.0 million from Fiocruz after September 30, according to its quarterly filing. It also raised about $4.9 million gross through further stock sales. Collections and share issuance both contributed funds, with different consequences for shareholders. Subsequent events.
The constructive case
Chiesi’s orders repeat and receivables convert to cash. Pfizer and Fiocruz provide additional demand. Protalix can cover a growing share of its clinical and manufacturing costs from product proceeds.
The cautious case
Order timing becomes uneven, inventory builds and research costs rise. A profitable quarter can coexist with a larger need for working capital or new shares to fund the next trial stage.
Latest PLX news
Nov 13, 2026
BlackRock reports Protalix holding at September 30
BlackRock filed its quarterly holdings report. The filing lists 4,200,737 Protalix shares across six rows at September 30, a Merlintrader calculation.
Nov 12, 2026
Renaissance Technologies files its September Protalix position
Renaissance Technologies reported 988,100 Protalix shares as of September 30 in its quarterly holdings disclosure.
Nov 10, 2026
Protalix discloses post-quarter collections and equity issuance
The September Form 10-Q reports approximately $9.3 million collected from Chiesi and $3.0 million from Fiocruz after quarter-end. Protalix also reported additional ATM sales.
Nov 10, 2026
Protalix BioTherapeutics Reports Third Quarter 2026 Financial and Business Results
Protalix BioTherapeutics reported third quarter 2026 results, with total revenues up $32.0 million year to date to $75.6 million from $43.6 million a year earlier. Net income was $4.0 million for the third quarter, up from $2.4 million in the third quarter of 2025. The company reaffirmed 2026 total revenue guidance of approximately $78.0 million to $83.0 million and reported cash, cash equivalents, and short-term bank deposits of $48.5 million as of September 30, 2026. Top-line results from the Phase 2 RELEASE study of PRX-115 are anticipated in the second half of 2027.
Nov 9, 2026
Protalix details Phase 1 PRX-115 analysis for ACR
Protalix released an exploratory analysis of individual participant data from its Phase 1 PRX-115 study on November 9. The ACR program listed the poster for November 10. The analysis associated longer measurable drug exposure with longer periods below the uric acid target.
Oct 15, 2026
Schedule 13G reports HOLD’s dated beneficial position
HOLD Alapkezelo Zrt. reported 4,157,791 shares and a rounded 5.2% position for the October 14 event. The filing certifies no purpose of influencing control. It is not proof of purchases on the filing day or current ownership.
Protalix business and clinical calendar
- March 9, 2026 — Protalix announced European approval of an every-four-weeks Elfabrio option for adults with Fabry disease who are stable on enzyme replacement therapy. Protalix collected the related milestone March 31. Approved and paid · March approval announcement · September filing
- June 25, 2026 — Shareholders increased the equity plan’s share limit. Approved by shareholders · Form 8-K
- September 29, 2026 — The RELEASE registry update lists recruiting status and about 150 expected participants. Registry update · ClinicalTrials.gov
- October 5, 2026 — Brazil’s health regulator announced Elfabrio registration for Fabry disease. The November business update describes authorization for both dosing intervals. Regulatory action · Anvisa notice · November update
- October 15, 2026 — HOLD Alapkezelő Zrt. filed a Schedule 13G reporting a 5.2 percent beneficial position. SEC filing · Schedule 13G
- November 9–10, 2026 — Protalix released a Phase 1 single-administration analysis of PRX-115 on November 9. The American College of Rheumatology program listed the abstract for November 10. Company and conference disclosures · November 9 release · Conference abstract
- November 10, 2026 — Third-quarter results published and the full-year outlook reiterated. Protalix’s chief executive officer was also scheduled to give a corporate overview at the Stifel 2026 Healthcare Conference that day. Results and conference · Form 8-K · results · event notice
- November 12–13, 2026 — Renaissance Technologies and BlackRock disclosed their September 30 positions. SEC filings · November 12 Form 13F · November 13 Form 13F
- November 24, 2026 — The Financial Industry Regulatory Authority (FINRA) is scheduled to publish short interest for November 13 settlement. Scheduled market data · FINRA publication calendar
- December 31, 2026 — Fiscal year closes and the measurement period for 2026 guidance ends. Reporting-period end · company outlook
- Second half of 2027 — Company target for top-line results from the Phase 2 RELEASE study. The registry estimates primary completion in December 2027 and study completion in June 2028. Company guidance and registry estimates · November update · trial record
Commercial products and the lead development study
Elfabrio
Chiesi commercializes the Fabry disease therapy. Protalix earns supply revenue and may receive payments when contractual milestones are achieved. Chiesi agreements.
Elelyso
Protalix supplies Pfizer with drug substance and sells the finished Gaucher therapy to Fiocruz in Brazil. Pfizer and Fiocruz.
PRX-115
RELEASE is a Phase 2 study for uncontrolled gout. Repeat-treatment outcomes will guide whether the candidate can advance. Clinical evidence and next steps.
Protalix BioTherapeutics deep dive: the full analysis
Product orders, milestone receipts and equity financing have supported different parts of the business. The Merlintrader Research Library collects our dated biotech stock research reports.
01 Bull, base and bear scenarios
Bull scenario · Partner orders translate into recurring cash
Chiesi’s demand grows enough to sustain regular deliveries. Pfizer and Fiocruz continue ordering, and spending on inventory becomes easier to manage as partners pay on schedule. RELEASE enrollment and follow-up proceed as planned, giving Protalix a chance to evaluate its lead pipeline asset while the approved products finance much of the work.
Stronger operating cash in quarters without the March milestone would support this scenario. That kind of result could give Protalix greater flexibility to choose between operating cash, partnerships and financing when planning a later trial. Sustainability would matter more than any one quarter of unusually large sales.
Base scenario · Commercial earnings remain uneven
Elfabrio sales grow over longer periods while bulk order timing creates uneven quarters. Elelyso remains a useful revenue source but demand from the two counterparties shifts with inventory and procurement. Protalix controls spending enough to advance Phase 2, with cash conversion and its ability to raise equity determining the pace of other work.
The annual revenue target can be met even if some quarters provide much more cash than others. Cash conversion will depend on receivable balances and on repeat sales after the partner collections already reported. Protalix would still have to decide how much new working capital and study spending the current portfolio can support.
Bear scenario · Working capital and development draw on the same resources
One or more partners slow ordering or stretch collections while inventory remains high. Supply, trade or operating costs rise, and clinical expenses become harder to reduce. In that situation some of the reported profit does little to improve the cash available to finance the next studies.
A weaker or delayed PRX-115 result would reduce the value of the work already funded. Issuing additional stock could extend the operating plan while spreading future outcomes across more shares. The lack of a term-loan maturity in the current balance sheet leaves Protalix with flexibility over financing timing, provided it can meet current commitments.
What would falsify this reading
The view that recurring deliveries can support a growing pipeline would weaken if revenue continued to rise while cash from operations fell and inventory and receivables kept growing. It would strengthen if cash flows remained positive over several ordinary shipment cycles without another milestone and after costs of continuing clinical work.
A cautious reading of Brazil deliveries would weaken if Fiocruz repeatedly placed new orders and paid promptly while stock rose only alongside confirmed demand. A single collection can improve current liquidity. Several cycles would be needed to judge whether the commercial arrangement consistently funds work elsewhere.
PRX-115 requires a different test. Long-lasting urate reduction under repeat treatment, combined with safety and tolerability in the intended patients, would improve the development case. Higher early exposure or a large effect after one administration carries less weight than those results. Trial and evidence · Cash conversion.
02 What Protalix sells and what it develops
Protalix develops and manufactures enzyme therapies. Its approved products are Elfabrio for adults with Fabry disease and Elelyso for Gaucher disease. The two therapies address different inherited conditions. Protalix licenses and supplies commercial partners, with the contracts determining which party sells into each market and how Protalix receives revenue. Quarterly business overview.
Dror Bashan is president and chief executive officer and Gilad Mamlok is chief financial officer. The company’s work includes plant-cell expression technology used to produce approved products as well as drug candidates. For shareholders the practical distinction is between products generating supply revenue and research assets that the company is still paying to develop. September liquidity reflected product collections, equity financing and the milestone payment received in March. Management signatures and business disclosures.
The pipeline includes PRX-115 in uncontrolled gout and the earlier PRX-119 program. Growing the pipeline adds costs for development and manufacturing readiness. Approved product volumes and related payments give Protalix more operating choices than a company relying entirely on development funding, while the supply contracts expose it to decisions by a small number of counterparties. Pipeline and risk discussion · November update.
03 The year-end revenue bridge
On November 10 Protalix said it expects to meet or exceed its prior full-year ranges. The total revenue range is approximately $78 million to $83 million and includes the $25 million already received in March. The product revenue ranges are $33 million to $35 million for Elfabrio excluding the milestone and $20 million to $23 million for Elelyso. Sales to partners and milestone consideration therefore need to be tracked separately. 2026 revenue guidance · August comparison.
Merlintrader calculation: against nine-month total revenue of $75.571 million, reaching the low end would require $2.429 million in the fourth quarter. Reaching the high end would require $7.429 million. That arithmetic uses the whole annual range including the milestone. Protalix issued guidance for the full year. November’s “meet or exceed” language leaves room for full-year total revenue above the earlier high end. Nine-month revenue statement · November outlook.
The product targets tell a different story. Goods delivered to Chiesi totaled $30.686 million through September, while sales to Pfizer and Fiocruz, the two Elelyso customers, combined for $18.395 million (Merlintrader calculation). These sales figures show how close the business is to its product outlook without adding a licensing milestone. Revenue, operating income and collections can still diverge once customer delivery and payment dates are taken into account. Customer-level sales.
04 Elfabrio and the Chiesi supply relationship
Chiesi commercializes Elfabrio through separate exclusive agreements for the United States and for markets outside it. Protalix supplies product and earns consideration on terms linked to Chiesi’s annual net sales. The disclosed range is 15 percent to 40 percent under the U.S. agreement and 15 percent to 35 percent outside the United States. The applicable rates depend on sales and contractual conditions. Chiesi’s own sales and the product revenue Protalix recognizes measure different transactions. Chiesi license and supply terms.
Shipments to Chiesi added $13.138 million of product revenue in the September quarter, compared with $8.763 million a year earlier. It was the largest customer in the goods line. Merlintrader calculation: Chiesi accounted for about 60.2 percent of quarterly goods revenue, based on $21.834 million of total goods sold. Its first-nine-month share was about 62.5 percent. These percentages measure Protalix’s revenue concentration. The number of patients receiving Elfabrio follows the partner’s commercial operations and is not disclosed through this breakdown.
Chiesi builds orders from its own operating forecasts. Protalix records product revenue upon delivery to Chiesi. A larger order can reflect changing demand or a decision to put more inventory into distribution. Protalix said bulk ordering can cause quarters without an order, including in periods of inventory reduction. A series of repeat orders and their corresponding collections would give more evidence about recurring cash than one large shipment. Customer sales and management’s description of orders.
The agreements also set out regulatory and commercial milestone opportunities. Protalix says it remains eligible for up to $270 million outside the United States and up to $740 million in the United States, subject to the specified conditions. The amounts are contractual caps tied to future milestones. The likelihood of satisfying each condition and the time required determine whether these provisions have value for funding. At September 30 the important realized amount was the $25 million already received following the European label expansion. Licensing arrangements and milestone disclosure.
European approval for the every-four-weeks option in adults stable on enzyme replacement was announced in March. A less frequent infusion may improve convenience for people who qualify. Adoption depends on the approved population, local access and decisions by patients and providers. The U.S. prescribing information describes the every-two-weeks schedule. Protalix disclosed that both intervals received marketing authorization in Brazil. The authorization lets Chiesi pursue Elfabrio sales in Brazil for Fabry disease. Fiocruz supplies a separate therapy for Gaucher disease. The filing did not report a specific cash payment or Brazilian sales target triggered by that Fabry authorization. March European approval announcement · U.S. approved prescribing information · Brazil registration · Protalix November update.
05 Elelyso orders from Pfizer and Fiocruz
Under its amended agreement, Protalix supplies Pfizer with the drug substance used to produce Elelyso at a fixed price through 2030, subject to the terms of the contract. Pfizer holds worldwide marketing rights with Brazil excluded. The agreement includes commitments on supply and potential financial consequences if Protalix cannot fulfill them. Fulfilling the agreement requires reliable manufacturing and supply planning. Pfizer agreement and supply provisions.
September-quarter deliveries to Pfizer generated $4.331 million, against $2.805 million a year earlier. Nine-month sales to Pfizer were $10.062 million, down from $15.431 million. Protalix attributed much of the nine-month decline to the comparison with 2025, when Pfizer purchased product in response to unexpected manufacturing issues. It attributed the latest quarterly increase mainly to deliveries falling in different reporting periods. The company’s sequence of sales should therefore be read alongside its description of inventory needs. Customer sales comparisons and delivery timing.
In Brazil, taliglucerase alfa is sold as Bio-Manguinhos alfataliglicerase under Protalix’s relationship with Fundação Oswaldo Cruz (Fiocruz). Its sales to Fiocruz were $4.365 million in the September quarter, compared with $6.105 million a year before. Nine-month sales were $8.333 million, versus $9.121 million. Fiocruz purchases at a fixed price and holds the product in inventory. The timing of its orders depends on factors including stock and public-sector purchasing. Brazil agreement and sales.
The Brazil agreement also provides for a staged transfer of manufacturing capabilities. Protalix says Fiocruz has not fulfilled certain purchase commitments, while sales under purchase orders continue and the parties are still discussing ways to increase sales to Brazil’s Ministry of Health. The company collected about $3.0 million from Fiocruz after September 30, according to the filing. The payment brought in cash from completed sales. Future orders and execution of contractual commitments are separate matters. Fiocruz commitments and subsequent collections.
Chiesi contributed the largest dollar increase in quarterly product revenue, while revenue from Fiocruz declined. The company’s goods revenue can rise with a change in customer mix even if parts of Elelyso soften. Changes in cost of revenue also reflect that mix. A better sales quarter can help finance new trials once money is collected and current manufacturing costs are funded. That requires a wider view than profitability by itself. Income statement and margins · Collections and working capital.
06 PRX-115 and the next clinical evidence
PRX-115 is an investigational enzyme treatment designed to lower urate. Protalix is studying it in uncontrolled gout. The candidate’s commercial case depends on how reliably it can lower urate over time and whether patients can tolerate repeated administration. Gout patients receiving ongoing treatment need a regimen that they can continue in practice. An early biological signal is a starting point for studying those outcomes. Clinical program update · Phase 2 registry.
The completed Phase 1 single-administration study included 64 participants, of whom 48 received PRX-115 and 16 received placebo. In November the company released an individual-participant analysis from three higher-dose groups. The analysis examined the relationship between measured drug exposure and urate reduction. Protalix reported that greater exposure was associated with longer reductions and that, in the highest group, mean urate remained below the study’s target for up to 12 weeks. The American College of Rheumatology abstract describes an early study with a single administration. It provides preliminary evidence on activity. November company analysis · Conference abstract and methods · Phase 1 study overview in the annual filing.
The earlier Phase 1 experience also included an anaphylactic reaction that resolved. An adverse reaction is relevant even when the candidate produces a clear laboratory effect. The planned patient population and repeat administrations can show different response and tolerability patterns from those observed after a single exposure. A useful later report will show how response changes over time and how many participants continued treatment, along with serious events and outcomes by treatment group. Clinical history and safety discussion · Phase 2 protocol summary.
RELEASE is the Phase 2 randomized study of PRX-115 in uncontrolled gout. Its September 29 registry update lists recruiting status and estimated enrollment of 150. The study evaluates multiple treatment schedules and includes a placebo comparison. The primary completion estimate is December 2027. Protalix says it anticipates top-line results in the second half of 2027. A registered primary completion estimate and the company’s expected public disclosure describe separate events and can change as enrollment and follow-up progress. ClinicalTrials.gov study design and timeline · Company timing.
For the business, the timing means that product orders and partner collections have to support ongoing work well before the Phase 2 result. A later study would require resources and a further development decision. The apparent value of a strong urate result depends on adverse events, duration of response and the cost of advancing the program. PRX-119 and other earlier work broaden the pipeline while the September reporting highlights RELEASE as a significant cash need over the next two years. Pipeline and expected cash requirements.
07 September results without another March milestone
Higher commercial deliveries and lower costs of revenue improved the September operating result from a year earlier. Net research and development expense also rose as the trial and other work advanced. The quarter’s result gives a measure of operations after the large March license milestone had already been recorded.
| U.S. dollars in thousands except per share and share counts | Q3 2026 | Q3 2025 | 9M 2026 | 9M 2025 |
|---|---|---|---|---|
| Goods revenue | 21,834 | 17,673 | 49,081 | 43,108 |
| License and research services revenue | 91 | 178 | 26,490 | 514 |
| Total revenue | 21,925 | 17,851 | 75,571 | 43,622 |
| Cost of revenues | (7,876) | (8,324) | (19,765) | (22,374) |
| Net research and development expense | (6,923) | (4,467) | (16,700) | (13,934) |
| Selling, general and administrative expense | (3,079) | (2,929) | (9,241) | (8,156) |
| Operating income or loss | 4,047 | 2,131 | 29,865 | (842) |
| Financial income, net | 575 | 108 | 758 | 10 |
| Income tax expense or benefit | 661 | (116) | 4,568 | 268 |
| Net income or loss | 3,961 | 2,355 | 26,055 | (1,100) |
| Basic earnings or loss per share | 0.05 | 0.03 | 0.33 | (0.01) |
| Diluted earnings or loss per share | 0.05 | 0.03 | 0.31 | (0.01) |
| Basic weighted-average common shares | 80,455,731 | 79,281,685 | 80,077,803 | 78,225,112 |
| Diluted weighted-average common shares | 83,586,774 | 80,814,564 | 83,000,983 | 78,225,112 |
Protalix consolidated statements of operations.
Protalix reported $0.091 million from licensing and research services for the quarter, with a decline in services provided to Chiesi. Nine-month licensing and research services revenue includes the $25 million milestone. Protalix earned $4.047 million in operating income in the September quarter, when product sales accounted for nearly all revenue. Future margins will depend on whether repeat shipments support the quarter’s customer mix and cost base. Revenue categories and cost of revenues.
Protalix recorded a $0.989 million research grant as a reduction of quarterly research and development expense and $3.089 million over nine months. The balance sheet includes a $3.030 million research grant receivable. Those amounts affect reported expense and assets. Cash timing depends on the mechanism and conditions. Merlintrader calculation: subtracting the $0.989 million quarterly incentive would leave $3.058 million in operating income with all other items held constant. This isolates one item and is distinct from a comprehensive adjusted earnings result. Notes 7 and 9 and September balance sheet.
08 Cash, deposits and working capital
At September 30, cash and cash equivalents were $22.035 million and short-term bank deposits were $26.503 million, a combined $48.538 million. Protalix also carried $0.729 million of restricted cash deposits, separately classified. Combined cash and short-term deposits were approximately $40.7 million at June 30 and $30.273 million at December 31, 2025. The rise reflects operating collections, financing proceeds and the timing of expenses and investment. A bank deposit can move between balance sheet lines without changing the combined balance. September balance sheet and cash flows · June filing.
Operations generated $15.529 million in nine months, compared with using $14.023 million in the same period of 2025. Protalix received $25 million from Chiesi on March 31 following the European Commission’s decision. Merlintrader calculation: subtracting only that receipt from reported nine-month operating cash gives negative $9.471 million. Other working capital movements, tax payments and operating expenses are still in that number. Annualizing the calculation would mask the timing of shipments and receipts. Statement of cash flows and milestone disclosure.
Merlintrader calculation: subtracting June’s cumulative $11.625 million from September’s $15.529 million gives positive quarterly operating cash of $3.904 million. The same subtraction in 2025 yields negative $3.732 million. This shows the latest quarter improved independently of the March receipt. The quarter’s $3.904 million of operating cash flow and $3.961 million of net income measure different aspects of the business. Protalix’s partners order ahead of their own use, and a shipment near period-end can raise earnings before the corresponding collection reaches the bank. June statement of cash flows · September statement of cash flows.
Inventory rose from $25.729 million in December to $34.297 million in September, and trade receivables climbed from $8.840 million to $13.913 million. The post-quarter collections described earlier are not part of the September 30 balances. Balance sheet and Note 10.
Nine-month investing outflow of $13.223 million included a net $11.065 million placed in bank deposits and $2.091 million spent on property and equipment. Financing generated $4.733 million, including $4.210 million in net at-the-market (ATM) proceeds and $0.523 million in proceeds from stock option exercises. Cash and equivalents increased $7.355 million after all categories and foreign exchange. The change in combined cash and deposits is more useful when cash is being shifted between those lines. Cash flow statement and equity notes.
The working-capital question going forward is whether new orders generate collections fast enough to fund the next manufacturing cycle. Margin expansion can coexist with slower cash conversion when production runs ahead of shipping. Follow inventories, trade receivables and operating cash alongside revenue. Working capital and customer disclosures.
09 Debt, commitments and liquidity outlook
At September 30, Protalix reported no outstanding borrowings. Total liabilities were $37.693 million, of which $30.233 million was current. Operating leases accounted for $1.685 million of current liabilities and $7.460 million of long-term liabilities. Trade accounts payable and accruals were $4.779 million and other accounts payable and accruals were $23.769 million. The company therefore retains material obligations even with the absence of financial debt on the balance sheet. September balance sheet.
Management said in the November 10 filing that then-current cash, equivalents and deposits were sufficient to support operations for at least 12 months from issuance of the financial statements. Management’s liquidity assessment extends into November 2027. ClinicalTrials.gov estimates that RELEASE will complete in June 2028. The company can adjust development investment and commercial production over the life of the study and retains the ability to issue stock. Liquidity and capital resources · RELEASE trial schedule.
Merlintrader reading: the financing considerations are the size and timing of product collections, manufacturing and clinical commitments, and management’s use of equity. A funded year of operations and a sales partnership can lessen near-term stress without funding every development decision. Supplier payments, leases and taxes draw on the same cash as trial and production spending. Progress toward a self-financing operation would be clearer in multiple periods without a milestone and with modest equity sales. Management’s discussion and risk factors.
The September filing also discusses uncertainty regarding U.S. tariffs on imported patented pharmaceutical products under the April proclamation. For companies outside the proclamation’s Annex III, the tariffs took effect September 29. Rates and exceptions depend on the products and commercial arrangements involved. The reported quarter provides a realized revenue and margin baseline. It does not quantify an eventual tariff charge or identify a confirmed impact in the years ahead. Customer agreements and the cost of producing in Israel remain more direct ways to follow the exposure. Quarterly risk factors · Federal Register proclamation.
10 ATM issuance, option grants and share count
Protalix reported 80,425,981 common shares outstanding at December 31, 2025, 80,571,642 at June 30, 2026, and 82,493,269 at September 30. The filing cover shows 84,318,923 on November 1. Merlintrader calculation: 1,798,325 ATM shares plus 27,329 shares from option exercises disclosed after September sum to 1,825,654, exactly the reported increase from September 30 through the November cover count. That difference is a transparent measure of issued shares. It does not require assumptions about unvested awards. Cover, equity statement and subsequent events · June equity statement.
In the September quarter the company sold 1,613,992 shares through its equity sales agreement with H.C. Wainwright for approximately $4.3 million gross. The nine-month cash statement lists $4.210 million net. The subsequent-event disclosure adds approximately $4.9 million of gross sales and approximately $0.1 million of related costs, along with approximately $50,000 in separate option exercise proceeds. Equity issuance improved access to cash and increased the number of shares participating in any future earnings. The two effects are both relevant to a per-share analysis. Note 5 and Note 10.
The company disclosed approximately $11.3 million of ATM capacity at September 30. Merlintrader calculation: subtracting approximately $4.9 million of subsequent disclosed gross sales yields roughly $6.4 million before any other activity. The two figures are rounded and the resulting balance is an estimate. The filed capacity and issued shares carry distinct dates. A new shelf or amendment can change available issuance even after that balance is used. Sales agreement disclosure.
Protalix granted options on 1,317,750 shares in Q3 at a weighted-average exercise price of $2.59 to officers, directors, employees and a consultant. It granted 702,925 restricted stock units to officers, directors and employees. The awards generally vest quarterly over three years. Common share issuance, restricted stock units and unexercised options have different timing and economic characteristics. The company’s diluted quarterly earnings per share used 83,586,774 weighted-average shares, including an effect of 3,131,043 from stock options and unvested restricted stock. That denominator is a quarterly average. The November count measures common shares outstanding on a specific date. Stock-based compensation and EPS notes.
Shareholders approved a 3,500,000-share increase in the 2006 stock incentive plan’s reserve on June 25, increasing it from 17,475,171 to 20,975,171 shares. Protalix filed a Form S-8 registration statement for the additional shares on August 12. The vote and the registration establish availability under the plan. Grants and settled exercises show when and how the shares affect the capital structure. The last outstanding ordinary warrants expired on March 11, 2025. Protalix had no warrants outstanding at September 30, 2026. Annual meeting results · August stock-plan registration · Warrants and equity activity.
11 Reported ownership and insider awards
HOLD Alapkezelő Zrt. reported 4,157,791 shares and a 5.2% position in an October 15 Schedule 13G. The cover identified October 14 as the triggering date. The filing used the 80,571,642 shares disclosed at June 30 as its denominator and reported sole voting and dispositive authority. The amount is useful as a dated, reported position. The later November cover count shows why percentages across schedules can move when the issuer raises equity. HOLD Schedule 13G · June denominator · November cover count.
BlackRock disclosed 4,046,650 shares and 5.02% at June 30 in its July 29 Schedule 13G. Reporting dates, account attribution and voting authority differ across schedules. Two managers can also report different categories of authority for securities they oversee. The individual disclosures establish which positions their filers reported and when. They give limited information about subsequent transactions or motives. BlackRock Schedule 13G.
Two managers filed distinct September-quarter Form 13F snapshots after Protalix reported results. Merlintrader calculation: the November 13 BlackRock filing lists a combined 4,200,737 PLX shares across six rows for the common stock identifier at September 30. The November 12 Renaissance Technologies filing lists 988,100. Schedules 13G separately report beneficial ownership and voting authority as of their respective reporting dates. BlackRock September holdings · Renaissance September holdings.
The Form 4 filed September 4 for President and Chief Executive Officer Dror Bashan reports a September 3 grant of 320,000 stock options at a contractual exercise price of $2.59 and 160,000 restricted stock units. These were compensation awards. An investor evaluating management alignment can follow vesting, actual exercises and later sales in subsequent Forms 4. The third-quarter filing says no director or officer adopted or terminated a covered trading arrangement during the quarter. CEO Form 4 · Part II Item 5 · SEC filing index.
12 Short interest and reported trading liquidity
FINRA’s consolidated series shows 3,480,033 shares sold short at the October 30 settlement date for PLX on NYSE American. The source gives 563,101 shares of average daily volume and a 6.18 days-to-cover ratio. On October 15, FINRA recorded 3,508,555 shares short, average daily volume of 1,070,752 shares and 3.28 days to cover. On September 30, FINRA recorded 3,040,042 shares short, average daily volume of 709,069 shares and 4.29 days to cover. FINRA consolidated equity short interest.
Merlintrader calculation: the October 30 count fell by 28,522 shares, about 0.81%, from mid-month while the comparison volume fell substantially. That explains how days to cover increased even as open positions declined. The ratio compares two reported figures. It measures neither a deadline by which positions must close nor the size of the buyer base on a particular day. The next scheduled publication for November 13 settlement data is November 24. Reported positions and volume · FINRA release calendar.
For the health assessment, listing status and several hundred thousand shares of observed average daily volume provide a baseline. The sharp change between the two October windows argues for a measured assessment of liquidity. Regular equity issuance can also change the denominator against which investors compare reported short positions. The settlement count is the cleanest anchor across dates in the absence of a comparable official float series. FINRA inputs · Issued shares and sales agreement.
13 Red flags and how to assess the business
The positive quarter came with three distinct exposures. Chiesi accounts for most product revenue, the positive nine-month operating cash flow included a single $25 million payment, and financing through stock continued even while liquidity improved. The next disclosure can change one without resolving the others. A bigger cash balance after stock issuance, for example, does not mean the products funded their own expansion. Rising customer collections would carry different implications for future share count. Revenue concentration, cash flows and equity.
The underlying valuation questions are the repeatable profit from drug supply, the working capital needed to achieve it and the costs and risks of getting PRX-115 through its next development decisions. Building a view of earnings from current commercial contracts requires allowance for shipment variability, grants, partner terms and manufacturing. The March milestone is already recognized in earnings and cash. Future contingent milestones and RELEASE are separate potential sources of value, tied to outcomes, dates and contractual conditions. Contracts and nine-month results · RELEASE registry.
Merlintrader reading: evidence of better cash generation would be several profitable delivery periods with stable or faster collections and limited additional share issuance. Evidence of a more fragile model would be falling goods revenue, a rise in receivables relative to shipments, or sustained outside financing for ordinary working capital. The most informative progress report would reconcile partner-level sales and cash generation with the budget for Phase 2. The company’s $78 million to $83 million 2026 view and the post-quarter collections disclosed on November 10 are starting points for those tests. Company outlook · Financial and subsequent-event reporting.
Merlintrader Health Score
2.95out of 5
Assessed November 18, 2026, on information through November 17.
Merlintrader calculation: 3.5 × 30% + 2.5 × 30% + 2.5 × 20% + 3.0 × 10% + 3.5 × 10% = 2.95/5.
Red flags
- Concentration. Chiesi generated $30.686 million of $49.081 million in nine-month goods revenue. Supply batches create timing risk for Protalix. Customer mix.
- Single receipt in operating cash. The $25 million March milestone materially changed the nine-month cash picture. Cash flow and milestone.
- Share issuance. Protalix raised about $4.3 million in gross ATM proceeds in Q3 and disclosed another $4.9 million in gross proceeds from post-quarter share sales. Notes 5 and 10.
- Development risk. Phase 2 RELEASE was recruiting and the Phase 1 urate analysis had limited scope. Clinical outcomes and the duration of any benefit remained open. Study record · Conference abstract.
- Customer commitments and collections. Fiocruz fell short of some purchase obligations, and Protalix describes ongoing sales and discussions. Brazilian agreement disclosure.
PLX Stock FAQ: Protalix BioTherapeutics Questions Answered
When does the next financial reporting period end for PLX?
December 31, 2026, is the end of the fiscal year and the period covered by Protalix’s latest revenue outlook. On November 10, Protalix said it expects to meet or exceed its guidance. It had announced no results release date by November 17. SEC fiscal-year information · Quarterly outlook.
Has the FDA approved Protalix’s Elfabrio?
The FDA approved Elfabrio in May 2023 for adults with confirmed Fabry disease. The European Union announced authorization of a four-week regimen in March 2026 for eligible adults stable on enzyme replacement therapy. FDA prescribing information · EMA authorization details.
How much cash does Protalix BioTherapeutics have?
At September 30, 2026, Protalix held $48.538 million in cash, equivalents and short-term deposits by Merlintrader calculation. The filing reported $22.035 million in cash and equivalents and $26.503 million in short-term deposits. Balance sheet and liquidity.
Is Protalix issuing new PLX shares?
In the quarter ended September 30, 2026, Protalix sold 1,613,992 shares through its at-the-market program. The November 10 filing also disclosed sales of 1,798,325 shares under the program after September 30. ATM and subsequent events.
When did Protalix BioTherapeutics report quarterly earnings?
Protalix reported third-quarter earnings on November 10, 2026. It earned $3.961 million on $21.925 million of revenue in the September quarter. Results release · Quarterly financial statements.
What does Protalix BioTherapeutics do?
As of September 30, 2026, Protalix supplied enzyme therapies for Fabry and Gaucher disease and was developing an investigational therapy for gout. It sells commercial product to Chiesi, Pfizer and Fiocruz under separate agreements. Business and customers.
When does Protalix expect Phase 2 RELEASE results for PRX-115?
On November 10, 2026, Protalix said it expects topline RELEASE results in the second half of 2027. The ClinicalTrials.gov record assigns an estimated December 2027 date to primary completion and June 2028 to completion of the study. Company release · Study record.
Sources
- September Form 10-Q · June Form 10-Q · 2025 Form 10-K · November 10 Form 8-K · September quarter results and outlook · August guidance
- EMA Elfabrio authorization · U.S. prescribing information · March European decision announcement · Brazilian Anvisa authorization
- November PRX-115 announcement · ACR abstract · RELEASE Phase 2 registry · Phase 1 registry
- Annual meeting results · Equity plan S-8 · CEO Form 4 · HOLD Schedule 13G · BlackRock Schedule 13G
- FINRA equity short interest · FINRA release calendar · U.S. tariff proclamation · Stifel conference notice · Protalix investor events · Protalix news archive
Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent journalism and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $PLX or any other security.
Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases, court records and market-data providers, and are stated with their reference dates. Data can change without notice. Readers should verify every figure against the primary source before acting on it.
Commercial biopharmaceutical businesses face manufacturing and supply disruptions, regulatory changes, competition for reimbursement, product concentration and safety risks. Development programs may require additional investment and can fail. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate.
Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.



